Masoom Abbas Haider MD, Presenter: Nothing to Disclose

Ashwini Kale, Abstract Co-Author: Nothing to Disclose

Igor Sitartchouk, Abstract Co-Author: Nothing to Disclose

Timothy P. Roberts PhD, Abstract Co-Author: Nothing to Disclose

Caroline Reinhold MD, Abstract Co-Author: Nothing to Disclose

John Trachtenberg MD, Abstract Co-Author: Nothing to Disclose

Ants Toi MD, Abstract Co-Author: Nothing to Disclose

Mostafa Elhilali, Abstract Co-Author: Nothing to Disclose

et al, Abstract Co-Author: Nothing to Disclose

In patients with locally recurrent prostate cancer after radiation therapy there is no reliable way of assessing the location or extent of intraprostatic tumor. This information would be valuable in planning local ablative therapies and assessing response to hormonal therapy. The purpose of this study was to determine the performance of dynamic contrast enhanced MRI (DCE-MRI) in assessing locally recurrent prostate cancer

Twenty-six patients with locally recurrent prostate cancer after radiation therapy underwent DCE-MRI. Prior to MRI all patients underwent systematic biopsy with 3 cores taken per side. DCE-MRI was performed using a1.5T MRI (GE) and a four element torso phased array coil using a 3D fast gradient echo sequence with a temporal resolution of 5-10 seconds, a slice thickness of 10 mm, a flip angle of 40 degrees. Omniscan was administered with a power injector at 2cc/s with a dose of 0.1mmol/kg. An area of increased signal in the peripheral zone of the same or greater intensity than the brightest portion of the central glad occurring within 20s of initial enhancement of the prostate was considered evidence of carcinoma. If one or more cores obtained from systematic sextant transrectal ultrasound biopsy was positive in a given prostate half, that prostate half was considered positive for carcinoma.

The overall sensitivity of DCE-MRI for prostate cancer was 96% (25/26). When considering each prostate half the sensitivity for cancer was 97% (37/38), specificity 78% (11/14), positive predictive value 92% (37/40) and negative predictive value 91% (11/12).

Early intense enhancement on DCE-MRI is a feature of locally recurrent prostate cancer. DCE-MRI has the potential to provide valuable information on local tumor extent planning of minimally invasive local therapy of the prostate and assessment of therapeutic response.

Haider, M, Kale, A, Sitartchouk, I, Roberts, T, Reinhold, C, Trachtenberg, J, Toi, A, Elhilali, M, et al, , Dynamic Contrast-enhanced MRI for Assessment of Locally Recurrent Prostate Cancer after Radiation Therapy.  Radiological Society of North America 2004 Scientific Assembly and Annual Meeting, November 28 - December 3, 2004 ,Chicago IL. http://archive.rsna.org/2004/4407818.html